Tivic Health Registers 400K Shares for Resale Linked to Statera Biopharma License Agreement
PorAinvest
sábado, 9 de agosto de 2025, 3:49 pm ET1 min de lectura
TIVC--
The registration statement, filed on August 8, 2025, details the terms of the offering. The shares being offered include 111,339 shares issued under Securities Purchase Agreements dated February 11 and March 31, 2025, and 51,504 shares issued on July 3, 2025, upon conversion of Series A Non-Voting Convertible Preferred Stock. Additionally, 237,201 shares are issuable upon conversion of additional Series A Preferred Stock [2].
Tivic Health Systems has agreed to pay certain expenses related to the registration of the offer and sale of its common stock. The company will not receive any proceeds from the sale of the shares by the selling stockholders. The selling stockholders will bear all commissions, discounts, concessions, and other selling expenses.
The registration statement also outlines the risks associated with investing in Tivic Health Systems' common stock. Investors should carefully read the "Risk Factors" section of the prospectus before making investment decisions.
The company's common stock is listed on the Nasdaq Capital Market under the symbol "TIVC." As of August 5, 2025, the closing price of the common stock was $3.38 per share.
References:
[1] https://seekingalpha.com/news/4482891-tivic-health-registers-400k-shares-for-resale-linked-to-statera-license-deal
[2] https://www.stocktitan.net/sec-filings/TIVC/s-3-tivic-health-systems-inc-shelf-registration-statement-3b9c2b1defcb.html
Tivic Health Systems is registering 400,044 shares of common stock for resale by selling stockholders, tied to the Exclusive License Agreement with Statera Biopharma. The agreement was signed on February 11 and amended on June 18, 2025. The stock issuance is a result of the agreement between the two companies.
Tivic Health Systems (NASDAQ: TIVC) has registered 400,044 shares of common stock for potential resale by selling stockholders, according to a recent SEC filing. The stock issuance is tied to an Exclusive License Agreement with Statera Biopharma, which was signed on February 11 and amended on June 18, 2025. The agreement involves the sale of shares in exchange for the license deal [1].The registration statement, filed on August 8, 2025, details the terms of the offering. The shares being offered include 111,339 shares issued under Securities Purchase Agreements dated February 11 and March 31, 2025, and 51,504 shares issued on July 3, 2025, upon conversion of Series A Non-Voting Convertible Preferred Stock. Additionally, 237,201 shares are issuable upon conversion of additional Series A Preferred Stock [2].
Tivic Health Systems has agreed to pay certain expenses related to the registration of the offer and sale of its common stock. The company will not receive any proceeds from the sale of the shares by the selling stockholders. The selling stockholders will bear all commissions, discounts, concessions, and other selling expenses.
The registration statement also outlines the risks associated with investing in Tivic Health Systems' common stock. Investors should carefully read the "Risk Factors" section of the prospectus before making investment decisions.
The company's common stock is listed on the Nasdaq Capital Market under the symbol "TIVC." As of August 5, 2025, the closing price of the common stock was $3.38 per share.
References:
[1] https://seekingalpha.com/news/4482891-tivic-health-registers-400k-shares-for-resale-linked-to-statera-license-deal
[2] https://www.stocktitan.net/sec-filings/TIVC/s-3-tivic-health-systems-inc-shelf-registration-statement-3b9c2b1defcb.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios